scholarly journals Mature Plasma Cell Count

2020 ◽  
Author(s):  
Keyword(s):  
Cell Count ◽  
Plasma Cell ◽  
Mature Plasma Cell

scholarly journals Phenotypic heterogeneity in aneuploid multiple myeloma indicates pre-B cell involvement

Blood ◽  
1988 ◽  
Vol 71 (4) ◽  
pp. 861-865
Author(s):  
J Epstein ◽  
B Barlogie ◽  
J Katzmann ◽  
R Alexanian
Keyword(s):  
Multiple Myeloma ◽  
B Cell ◽  
Tumor Cells ◽  
Plasma Cell ◽  
Lymphoblastic Leukemia ◽  
Cell Markers ◽  
Aneuploid Tumor ◽  
Beta 2 Microglobulin ◽  
Normal Differentiation ◽  
Mature Plasma Cell

The expression of early and mature B cell markers, surface beta 2- microglobulin (B2M) and cytoplasmic immunoglobulin (clg) by aneuploid tumor cells in bone marrow aspirates from 44 patients with multiple myeloma was evaluated by correlated DNA immunofluorescence flow cytometry. Myeloma tumor cells of almost 90% of the patients contained monoclonal clg and expressed the mature plasma cell antigen R1–3 as well as surface B2M; common acute lymphoblastic leukemia antigen (CALLA) was present in 55%, B2 in 17%, and B4 in 23% of samples studied. Coexpression of CALLA and clg in 46% of all patients identified a novel myeloma phenotype without known counterpart in the normal differentiation of B cells. CALLA and clg were independently expressed and gave rise to CALLA+/clg-, CALLA+/clg+, and CALLA-/clg+ cells. The association of CALLA and mature plasma cell markers may define discrete stages of neoplastic plasma cell differentiation.

scholarly journals Inhibition of DEPDC1A, a Bad Prognostic Marker in Multiple Myeloma, Delays Growth and Induces Mature Plasma Cell Markers in Malignant Plasma Cells

PLoS ONE ◽  
2013 ◽  
Vol 8 (4) ◽  
pp. e62752 ◽  
Author(s):  
Alboukadel Kassambara ◽  
Matthieu Schoenhals ◽  
Jérôme Moreaux ◽  
Jean-Luc Veyrune ◽  
Thierry Rème ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Prognostic Marker ◽  
Plasma Cell ◽  
Plasma Cells ◽  
Cell Markers ◽  
Mature Plasma Cell

Utility Of An Algorithm For Use Of Plerixafor In Filgrastim-based Hematopoietic Progenitor Cell Mobilization In Patients With Plasma Cell Myeloma Treated With Carfilzomib-Lenalidomide-Dexamethasone.

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 906-906
Author(s):  
Susan F. Leitman ◽  
Nishant Tageja ◽  
Neha Korde ◽  
Yu Ying Yau ◽  
Sheila Phang ◽  
...  
Keyword(s):  
Cell Count ◽  
Plasma Cell ◽  
Hematopoietic Progenitor Cell ◽  
Plasma Cell Myeloma ◽  
Hematopoietic Progenitor ◽  
Evening Dose ◽  
Single Procedure ◽  
Regression Formula ◽  
Cd34 Cells ◽  
Cell Mobilization

Abstract Mobilization of hematopoietic progenitor cells (HPC) for subsequent autologous transplantation is difficult in patients with plasma cell myeloma (PCM) due to poor marrow reserve. Targeted HPC yields are generally not achieved in a single apheresis procedure without use of plerixafor as a supplement to standard filgrastim. Strategies to limit use of plerixafor, due to its expense, to cases of poor CD34 mobilization have been developed, but their applicability in patients receiving the novel induction regimen carfilzomib-lenalidomide-dexamethasone (CRD) (Blood 2012;120:1801) has not been described. We prospectively studied the CD34 cell mobilization responses of PCM patients following CRD induction, using a CD34 cell predictive algorithm to determine when plerixafor should be added to the mobilization regimen. Thirty patients, including 23 with PCM and 7 with smoldering PCM, mean age 55 (range 40-72), 47% male, received 4 to 7 cycles of CRD (median, 5 cycles), with the last dose of lenalidomide given at least one week prior to mobilization. Filgrastim 10-16 mcg/kg/day was given as a single evening dose for 5 days, with circulating CD34 count assessed 12 hours after the 4th dose. The pre-apheresis CD34 count after the 5th dose of filgrastim was predicted to be 10% greater than that after the 4th dose; this prediction was validated with an actual pre-apheresis CD34 count obtained the following day. Prior mobilization data derived from healthy HPC apheresis donors was used to generate a regression formula, y=0.45x+0.86, where x=the pre-apheresis circulating CD34 count after the 5th dose of filgrastim, and y=the expected yield of the apheresis procedure, expressed as millions of CD34 cells harvested per liter processed. Targeted yield was ≥ 4 x 106 CD34 cells/kg, with minimum acceptable yield ≥ 2 x 106 CD34 cells/kg. Plerixafor 240 mcg/kg was given with the 5th dose of filgrastim, 8-10 hours prior to apheresis, if the regression equation predicted a CD34 cell yield of < 4 x 106 CD34 cells/kg in a single procedure with a maximum of 30 liters processed. The actual volume processed was based on the stat blood CD34 count drawn immediately prior to apheresis. Procedures were performed on the Cobe Spectra device; continuous intravenous calcium was used to mitigate citrate toxicity. Central lines were required in 67% of subjects. Mean CD34 cell count in the entire group after the 4th dose of filgrastim was 29/uL (range 2-88/uL). Using the regression formula as a guide, 17/30 (57%) of patients received plerixafor. CD34 counts increased 4.2-fold in patients receiving plerixafor, from 15 ± 9/uL (m ± SD) on the day prior to apheresis to 53 ± 30/uL immediately pre-apheresis; CD34 counts did not change in patients who received filgrastim alone (from 48 ± 17/uL to 45 ± 19/uL). Guided by the stat pre-apheresis CD34 count, the volume processed in the first apheresis procedure was the same, 23 ± 7 (range 12-30) liters, with or without plerixafor. CD34 cells were collected with 72 ± 14% efficiency. First-procedure CD34 cell yields were 6.4 ± 2.5 x 106/kg (range 2.5-10.1) with supplemental plerixafor vs 5.8 ± 2.5 x 106/kg (range 1.1-9.3) with filgrastim alone. Only 2/30 patients underwent a second procedure; neither received plerixafor prior to the first procedure, and both received it prior to the second. In one patient, criteria for plerixafor administration were met, but the drug was inadvertently not given prior to the first procedure; in the second patient, an unexpectedly low pre-apheresis CD34 count was traced to inadequate self-administration of the 5th dose of filgrastim. All 30 patients achieved the minimum CD34 collection goal of ≥ 2 x 106 cells/kg and 29/30 did this in one procedure. The higher targeted collection goal of ≥ 4 x 106 CD34 cells/kg was achieved in a single procedure by 76% of patients in both the plerixafor group and the filgrastim-alone group. There was a trend for higher cumulative lenalidomide and carfilzomib doses to be associated with lower CD34 mobilization responses to filgrastim. Induction treatment with CRD does not appear to impair HPC mobilization response to filgrastim in patients with PCM, compared to older regimens. An algorithm that uses the CD34 cell count after 4 doses of filgrastim to predict the following day’s pre-apheresis CD34 count and thus determine whether plerixafor supplementation is needed, was useful in identifying the 40% of CRD-treated myeloma patients who do not need plerixafor. Disclosures: No relevant conflicts of interest to declare.

scholarly journals Vinorelbine-Based Hematopoietic Stem-Cell Mobilization: A More Effective, Low-Cost Alternative to Conventional Chemotherapy

Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 4762-4762
Author(s):  
Bruno Kosa Lino Duarte ◽  
Marcos Paulo Colella ◽  
Fernando Vieira Pericole Souza ◽  
Gabriela G Yamaguti-Hayakawa ◽  
Jose Francisco Comenalli Marques ◽  
...  
Keyword(s):  
Stem Cell ◽  
Cell Count ◽  
Plasma Cell ◽  
Research Funding ◽  
Low Cost ◽  
Conventional Chemotherapy ◽  
Chemotherapy Group ◽  
Cd34 Cells ◽  
Plasma Cell Disorders ◽  
Pbsc Mobilization

Abstract INTRODUCTION: Autologous stem cell transplantation (ASCT) is the cornerstone of the treatment of several hematological malignancies, including multiple myeloma (MM) and aggressive and relapsed/refractory lymphomas. The mobilization of peripheral blood stem-cells (PBSC) for ASCT, however, is not always possible, with failure rates around 20%. Although the introduction of drugs such as plerixafor has greatly improved on this issue, they are still expensive and inaccessible in lower-income countries. The use of chemomobilization with drugs such as cyclophosphamide, etoposide, and others are a more affordable option, but they still lead to severe neutropenia, and in some settings to longer inpatient stays, with the associated costs. Vinorelbine is a vinca alkaloid which has already been reported to be effective in PBSC mobilization in combination with granulocyte growth-factor (G-CSF). We tested whether vinorelbine-based strategy for PBSC mobilization would be more effective and less resource-consuming than mobilization with conventional chemotherapy in combination with GCSF. METHODS: This is a retrospective, single-center analysis of the 74 patients with plasma cell disorders and lymphomas who underwent PBSC mobilization in our institution from January 2016 until May 2018. Until March 2017 PBSC mobilization at our institution was done with cyclophosphamide 2 gm/sqm plus G-CSF, for plasma-cell disorders, or with conventional chemotherapy regimens, such as ICE (ifosfamide, carboplatin and etoposide) and DHAP (dexamethasone, cytarabine and cisplatin) plus G-CSF for lymphomas. Peripheral CD34+ cells were counted daily after white blood cells reached > 1000 cells/μl, and leukapheresis was performed on the first day of peripheral CD34+ cell count > 10/μl, with a target of at least 2x106CD34+ cells/kg. Due to local limitations and the unpredictability of the day of PBSC harvesting, the whole procedure-from chemotherapy administration to apheresis-was done in the inpatient setting. From March 2017 onwards, in an effort to reduce costs and increase efficacy, a vinorelbine-based protocol for mobilization with a 35 gm/sqm dose on day one, GCSF 12-16 mcg/kg/day from day 4 onwards and PBSC harvesting on day 8, or latter, when peripheral CD34+ cell count was higher than 10/μl was implemented for all patients, irrespective of their diagnosis. RESULTS: Patients' characteristics are summarized in Table 1. Seventy-four patients underwent mobilization, 38 (51.3%) with vinorelbine and 36 (47.3%) with conventional chemotherapy, with an 81.1% success rate. Patients had a median age of 54 years, with a median of one previous treatment line, which included radiotherapy in 22.4% of patients. Plasma-cell disorders were the most frequent diagnosis (59.5%). Due to a shortage of melphalan, only 52.7% of patients have proceeded to ASCT so far. Vinorelbine-based PBSC mobilization resulted in higher success rates (92.1% vs. 69.4%, p=0.017), lower length of hospital stay (median of 3 vs. 16 days, p<0.001), more predictable day of the first leukapheresis (median 7 days after chemotherapy, range 7-9 vs. 10 days, range 9-18) and a higher count of peripheral CD34+cells prior to leukapheresis (median 47.74 vs. 27.24 cells/μl, p=0.08) than mobilization with conventional chemotherapy-regimens (Figure 2). Patients in both groups were comparable regarding all variables depicted in Table 1, except for failure in a previous PBSC mobilization attempt (18.4% in the vinorelbine group vs. 2.8% in the conventional chemotherapy group, p=0.056). Two (5.3%) patients in the conventional chemotherapy group developed febrile neutropenia (FN), one of whom died. No episodes of FN or death were observed in the vinorelbine group. Progression-free survival and time for neutrophils engraftment after ASCT did not differ between groups (Figure 2). Direct costs of both strategies were roughly the same. CONCLUSIONS: Vinorelbine is a safe, effective and less costly strategy for PBSC mobilization in patients undergoing ASCT. It is associated with less toxicity and mobilization failures, shorter hospital length of stay and yields higher CD34+ blood cell counts, all of which decrease the indirect costs associated with PBSC, without loss of efficacy. Vinorelbine is a low-cost effective alternative to PBSC mobilization that can be useful in resource-constrained settings, where access to costly drugs, such as plerixafor, is limited. Disclosures De Paula: Hematology and Transfusion Medicine Center, University of Campinas: Employment. Ozelo:Pfizer: Honoraria, Research Funding, Speakers Bureau; Shire: Honoraria, Research Funding, Speakers Bureau; Grifols: Honoraria; Novo Nordisk: Honoraria, Research Funding, Speakers Bureau; Bioverativ: Honoraria, Research Funding; BioMarin: Honoraria, Speakers Bureau.

Prognostic significance of day+14 plasma cell count after initial induction therapy in Acute Myeloid Leukemia.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e18056-e18056
Author(s):  
Abhishek Avinash Mangaonkar ◽  
Rohini Chintalapally ◽  
Ashis Mondal ◽  
Ravindra B. Kolhe ◽  
Vamsi Kota
Keyword(s):  
Acute Myeloid Leukemia ◽  
Cell Count ◽  
Plasma Cell ◽  
Induction Therapy ◽  
Myeloid Leukemia ◽  
Prognostic Significance ◽  
Acute Myeloid

scholarly journals Phenotypic heterogeneity in aneuploid multiple myeloma indicates pre-B cell involvement

Blood ◽  
1988 ◽  
Vol 71 (4) ◽  
pp. 861-865 ◽  
Author(s):  
J Epstein ◽  
B Barlogie ◽  
J Katzmann ◽  
R Alexanian
Keyword(s):  
Multiple Myeloma ◽  
B Cell ◽  
Tumor Cells ◽  
Plasma Cell ◽  
Lymphoblastic Leukemia ◽  
Cell Markers ◽  
Aneuploid Tumor ◽  
Beta 2 Microglobulin ◽  
Normal Differentiation ◽  
Mature Plasma Cell

Abstract The expression of early and mature B cell markers, surface beta 2- microglobulin (B2M) and cytoplasmic immunoglobulin (clg) by aneuploid tumor cells in bone marrow aspirates from 44 patients with multiple myeloma was evaluated by correlated DNA immunofluorescence flow cytometry. Myeloma tumor cells of almost 90% of the patients contained monoclonal clg and expressed the mature plasma cell antigen R1–3 as well as surface B2M; common acute lymphoblastic leukemia antigen (CALLA) was present in 55%, B2 in 17%, and B4 in 23% of samples studied. Coexpression of CALLA and clg in 46% of all patients identified a novel myeloma phenotype without known counterpart in the normal differentiation of B cells. CALLA and clg were independently expressed and gave rise to CALLA+/clg-, CALLA+/clg+, and CALLA-/clg+ cells. The association of CALLA and mature plasma cell markers may define discrete stages of neoplastic plasma cell differentiation.

scholarly journals Management of Primary Plasma Cell Leukemia Remains Challenging Even in the Era of Novel Agents

2021 ◽  
Vol 14 ◽  
pp. 263485352199938
Author(s):  
Chakra P Chaulagain ◽  
Maria-Julia Diacovo ◽  
Amy Van ◽  
Felipe Martinez ◽  
Chieh-Lin Fu ◽  
...  
Keyword(s):  
Cell Count ◽  
Plasma Cell ◽  
Peripheral Blood ◽  
Pet Scan ◽  
Plasma Cell Leukemia ◽  
Novel Agents ◽  
Cell Transplant ◽  
Cell Leukemia ◽  
Hematopoietic Stem ◽  
Primary Plasma Cell Leukemia

Primary plasma cell leukemia (PCL) is a rare and aggressive variant of multiple myeloma (MM). PCL is characterized by peripheral blood involvement by malignant plasma cells and an aggressive clinical course leading to poor survival. There is considerable overlap between MM and PCL with respect to clinical, immunophenotypic, and cytogenetic features, but circulating plasma cell count exceeding 20% of peripheral blood leukocytes or an absolute plasma cell count of >2000/mm3 distinguishes it from MM. After initial stabilization and diagnosis confirmation, treatment of PCL in a fit patient typically includes induction combination chemotherapy containing novel agents typically, with proteasome inhibitors (such as bortezomib) and immunomodulatory drugs (eg, lenalidomide), followed by autologous hematopoietic stem cell transplant (HSCT) and multidrug maintenance therapy using novel agents post-HSCT. Long-term outcomes have improved employing this strategy but the prognosis for non-HSCT candidates remains poor and new approaches are needed for such PCL patients not eligible for HSCT. Here, we report a case of primary PCL, and a comprehensive and up to date review of the literature for diagnosis and management of PCL. We also present the findings of Positron Emission Tomography (PET) scan. Since PCL is often associated with extra-medulary disease, including PET scan at the time of staging and restaging may be a novel approach particularly to evaluate the extra-medullary disease sites.

scholarly journals IgG4-related disease: can non-classical histopathological features or the examination of clinically uninvolved tissues be helpful in the diagnosis?

2012 ◽  
Vol 65 (11) ◽  
pp. 963-969 ◽  
Author(s):  
Emma L Culver ◽  
Adrian C Bateman
Keyword(s):  
Cell Count ◽  
Plasma Cell ◽  
Supporting Evidence ◽  
Diagnostic Features ◽  
Histopathological Features ◽  
Related Disease ◽  
Igg4 Related Disease ◽  
Multisystem Involvement ◽  
Immune Mediated ◽  
Serum Igg4

IgG4-related disease (IgG4-RD) is an increasingly recognised inflammatory and fibrosing condition that commonly shows multisystem involvement. The disease may mimic malignancy and other inflammatory or immune-mediated disorders, but usually has a good response to corticosteroid therapy, underlining the requirement for recognition of the condition. Accurate diagnosis requires careful interpretation of varying combinations of serum IgG4 levels, radiological features and characteristic histopathological appearances within an appropriate clinical setting. The presence of ‘classical’ histopathological features together with an elevated tissue IgG4+ plasma cell count and IgG4 to IgG ratio is often diagnostic and at the very least can strongly support a clinicopathological diagnosis of IgG4-RD. The authors describe the most recent diagnostic criteria for IgG4-RD, especially the histopathological features. The authors then discuss the merits of examining tissues that may be more easily obtainable than those that commonly show the ‘classical’ histopathological features, but within which not all of these ‘diagnostic’ features may be present. The authors conclude that while a combination of ‘classical’ histopathological features and an elevated tissue IgG4+ plasma cell count is the gold standard for diagnosis, examination of tissues that show some but not all of these features can, in the appropriate context, provide useful supporting evidence for a clinicopathological diagnosis of IgG4-RD.

Sign in / Sign up

Export Citation Format

Share Document